R

Revance Therapeutics
D

RVNC

3.36000
USD
-0.415
(-10.99%)
Market Closed
Volume
41,562
EPS
0
Div Yield
0
P/E
-2
Market Cap
604,247,039
OverviewSignalsIdeasNews
Related Instruments
    ABT
    4.220
    (3.98%)
    110.150 USD
    BDX
    -4.995
    (-2.07%)
    236.055 USD
    B
    BHC
    0.07000
    (1.16%)
    6.10000 USD
    BSX
    1.315
    (1.78%)
    75.170 USD
    EW
    -1.220
    (-1.94%)
    61.830 USD
    ISRG
    6.98
    (1.57%)
    451.27 USD
    R
    RGEN
    -1.970
    (-1.18%)
    165.630 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    SYK
    5.59
    (1.71%)
    332.94 USD
News

Title: Revance Therapeutics

Sector: Healthcare
Industry: Biotechnology
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.